Director Charles J. Casamento of Eton Pharmaceuticals, Inc. filed a Form 4 on November 10, 2026, disclosing the exercise of four stock options and the same-day sale of all resulting shares of common stock.

Key Highlights

  • Four option tranches exercised: Casamento exercised stock options with exercise prices of $7.31, $3.58, $8.61, and $3.78 per share on November 10, 2026, acquiring a combined 80,555 shares of common stock.
  • All acquired shares sold: The 80,555 shares were sold across five separate tranches on November 10, 2026, with weighted average prices ranging from $64.3287 to $67.8695 per share.
  • Sale price ranges disclosed: Individual tranche prices spanned from a low of $63.755 to a high of $67.975, with each tranche executed at multiple prices per the filing's footnotes.
  • Zero directly held shares remaining: Following all transactions, Casamento's direct beneficial ownership of common stock stood at 0 shares.
  • Remaining derivative securities: According to the filing, 29,000 stock options with an exercise price of $3.78 remain beneficially owned directly by Casamento after the reported transactions.
  • Filing role: Casamento is identified as a Director of Eton Pharmaceuticals, Inc., traded on NASDAQ:ETON.

Director Casamento's Option Exercises and Share Sales at Eton Pharmaceuticals

According to the Form 4 filed with the SEC on November 10, 2026, Director Charles J. Casamento exercised four previously granted stock options in Eton Pharmaceuticals, Inc. The four exercises, each coded as transaction type "M," covered 12,500 shares at $7.31, 27,400 shares at $3.58, 19,655 shares at $8.61, and 21,000 shares at $3.78 per share. The filing notes that each option had vested on a quarterly basis over 12 months from its respective grant date, with the last of the four becoming fully exercisable on February 7, 2023.

The same day, Casamento disposed of all 80,555 acquired shares through five separate open-market sale tranches, each reported with a weighted average price. The tranches covered 6,380 shares at a weighted average of $64.3287 (ranging from $63.755 to $64.685), 14,715 shares at $65.3249 (ranging from $64.76 to $65.74), 22,601 shares at $66.2615 (ranging from $65.76 to $66.75), 33,956 shares at $67.1103 (ranging from $66.76 to $67.61), and 2,903 shares at $67.8695 (ranging from $67.76 to $67.975). The filing states that full detail on prices at each separate trade is available upon request to the SEC staff, the issuer, or a security holder.

Eton Pharmaceuticals is a specialty pharmaceutical company. After all reported transactions, Casamento's direct holdings of common stock fell to zero, while 29,000 stock options with an exercise price of $3.78 per share remained directly beneficially owned, according to the filing. The Form 4 was signed by Judith Matthews on Casamento's behalf on November 10, 2026, pursuant to an authorization described in the filing's remarks section.

What Was Disclosed

The filing disclosed that Director Charles J. Casamento exercised four stock options totaling 80,555 shares of Eton Pharmaceuticals common stock and sold all resulting shares on November 10, 2026, leaving zero directly held common shares and 29,000 options still outstanding.